Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Crespo G,
Keywords: G3 NEN, epidemiology, survival, patterns of care, response to chemotherapy,
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Alonso T,
Keywords: GEP-NEN, tumor registry, survival, prognosis, epidemiology,
Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jimenez Fonseca P
Authors: Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A,
Keywords: somatostatin analogues, surrogate, PFS, OS, correlation, kendall,
Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Jimenez-Fonseca P, Fernandez del Valle A, Solis M, Garcia Carbonero R, Custodio A,
Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Lamarca A, Barriuso J, Castaño A,
Keywords: Bayesian model, octreotide, lanreotide, progression-free survival, efficacy,